AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Genencor Forms Strategic Collaboration With Johns Hopkins.(Brief Article)
2002 JAN 30 - (NewsRx.com & NewsRx.net) -- Genencor International, Inc., (GCOR) has formed a two-year extendable collaboration with the Johns Hopkins University School of Medicine (JHU) for the research of therapeutic vaccines and other immunotherapies targeting cancers and oncogenic viruses.
Genencor has also received a worldwide exclusive license to proprietary technologies related to antigen targeting and dendritic cell activation, including costimulatory genes. This collaboration solidifies the foundation of a preeminent therapeutic vaccine platform at Genencor.
"We are very pleased to be working with the world-renowned team of Drs. Drew Pardoll and T.C. Wu," said Debby Jo Blank, chief business officer of health care for Genencor. "This is a full partnership working to leverage outstanding academic research into product development. With the addition of the JHU relationship, Genencor has successfully assembled the best technologies available in immunotherapeutics, which will enable us to develop a renewable pipeline for therapeutic vaccines. We have now achieved our initial goals related to building a new business for Genencor in therapeutic vaccines."
Genencor will work closely with and support ongoing research in the laboratories of Pardoll and Wu, who have conducted extensive preclinical animal studies on a number of advanced molecular vaccine constructs that have caused tumor regression and extended survival. Genencor is hopeful that this technology will prove effective in humans.
Thus far, therapeutic vaccines in development have failed to elicit an immune response strong enough to eliminate the target virus. Through a series of strategic collaborations, Genencor has developed a novel platform for therapeutic vaccine development that it believes will overcome this problem. Last summer, the company announced two key collaborations - the first with Epimmune to develop therapeutic vaccines for hepatitis B virus (HBV), hepatitis C virus (HCV) and human ...
- Genencor Solidifies Vaccine Platform Through Strategic Collaboration With Johns...
- Press release article from: PR Newswire January 7, 2002 700+ words
...ALTO, Calif. -- Genencor International, Inc...collaboration with the Johns Hopkins University School of...oncogenic viruses. Genencor has also received a...of the agreement, Johns Hopkins University will receive...future product sales. Genencor will also fund research...
- Genencor Reports Fourth Quarter and Year-End Financial Results.
- Press release article from: PR Newswire February 5, 2002 700+ words
...the course of the year. For Genencor, it was a year of progress...Over the course of 2001, Genencor achieved several significant...and, after year end, with Johns Hopkins, which added valuable technology and product candidates to Genencor's immunotherapeutics program...
- GENENCOR, SEATTLE GENETICS ALIGN TO DEVELOP CANCER THERAPEUTICS.(Brief Article)
- Magazine article from: BIOWORLD Today Coghill, Kim January 8, 2002 700+ words
...Aside from TEPT, other Genencor technologies included in the...capabilities. Also Monday, Genencor said it formed a two-year...collaboration with Baltimore-based Johns Hopkins University School of Medicine...and oncogenic viruses. Both Genencor and Seattle Genetics are fairly...
- Genencor Sells Its Therapeutic Vaccine Program to Innogenetics in Multi-Million...
- Press release article from: PR Newswire March 30, 2004 700+ words
Genencor International, Inc. today announced...commercialize current product candidates in Genencor's vaccine product portfolio as well...intellectual property and technology held by Genencor. Genencor will recognize license fees...
- Genencor Outlines Health Care Plans.
- Press release article from: PR Newswire June 13, 2001 700+ words
...Calif., June 13 /PRNewswire/ -- Genencor International, Inc. (Nasdaq: GCOR...its plans for the health care market. Genencor will leverage its broad technology base...very excited about the possibilities for Genencor," said W. Thomas Mitchell, chairman...
- GENENCOR EXPANDS ITS PRESENCE IN JAPAN.
- News wire article from: AsiaPulse News April 30, 2004 700+ words
...share of joint venture with Kyowa Hakko - Genencor International, Inc. and Kyowa Hakko Kogyo Co., Ltd., announced today that Genencor has assumed majority ownership and controlling...companies' eight-year old joint venture. Genencor has taken this step in order to more...
- Genencor International Signs Exclusive Agreement With Danisco A/S to Develop...
- Press release article from: PR Newswire October 31, 2000 700+ words
...N.Y., Oct. 31 /PRNewswire/ -- Genencor International (Nasdaq: GCOR) today...provides up to $20 million in funding for Genencor's R&D efforts. The agreement establishes Genencor as Danisco's exclusive partner for...
- Genencor International and DuPont Expand R&D Collaboration to Make Key Biobased...
- Press release article from: PR Newswire March 12, 2001 700+ words
...Del., March 12 /PRNewswire/ -- Genencor International (Nasdaq: GCOR) and DuPont...Under the terms of the agreement, Genencor will receive research and development...the collaboration that began in 1995, Genencor and DuPont have focused on the bioproduction...
Source: HighBeam Research, Genencor Forms Strategic Collaboration With Johns Hopkins.(Brief...